Business decisions for advancing or terminating an investigational drug in development or a compound in discovery are best made using “minimally acceptable standards.” These are primarily established by marketing groups, with input from R&D.
Do your best to eliminate fads and hype in management styles and be skeptical of all claims by vendors.
Truly great scientists do not generally make great managers. Creative scientists must be encouraged, stimulated and rewarded so they are happy to remain creative scientists.
Bert Spilker, PhD, MD is an independent consultant who was most recently the Senior Vice President of Scientific and Regulatory Affairs for PhRMA. He is the founder of Bert Spilker & Associates (BS&A).
